Article
Oncology
J. Randolph Hecht, Kyriakos P. Papadopoulos, Gerald S. Falchook, Manish R. Patel, Jeffrey R. Infante, Raid Aljumaily, Deborah J. Wong, Karen A. Autio, Zev A. Wainberg, Todd M. Bauer, Milind Javle, Shubham Pant, Johanna Bendell, Annie Hung, Navneet Ratti, Peter VanVlasselaer, Rakesh Verma, Joseph Leveque, Sujata Rao, Martin Oft, Aung Naing
Summary: The study demonstrated that pegilodecakin+FOLFOX had an acceptable tolerability profile in PDAC patients, with promising efficacy when used in combination therapy.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Medicine, General & Internal
Ning Li, Yuan Zhu, Lu-Ying Liu, Yan-Ru Feng, Wen-Ling Wang, Jun Wang, Hao Wang, Gao-Feng Li, Yuan Tang, Chen Hu, Wen-Yang Liu, Hua Ren, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Yu Tang, Ning-Ning Lu, Bo Chen, Shu-Nan Qi, Xin-Fan Liu, Ye-Xiong Li, Jing Jin
Summary: The addition of oxaliplatin to postoperative capecitabine-based chemoradiotherapy did not improve treatment efficacy but increased the risk of severe acute toxic effects. Postoperative capecitabine with radiotherapy plays a fundamental role in the treatment of locally advanced rectal cancer.
Article
Oncology
Seung Tae Kim, Sun Young Kim, Jeeyun Lee, Seong Hyeon Yun, Hee Cheol Kim, Woo Yong Lee, Tae Won Kim, Yong Sang Hong, Seok-Byung Lim, Ji Yeon Baek, Jae Hwan Oh, Joong Bae Ahn, Sang Joon Shin, Sae-Won Han, Seong Geun Kim, Seok Yun Kang, Sun Jin Sym, Dae Young Zang, Yeul Hong Kim, In Sil Choi, Jung Hun Kang, Min-Ji Kim, Young Suk Park
Summary: This study suggests that reducing the duration of oxaliplatin treatment from 6 months to 3 months, in combination with fluoropyrimidine, may be an alternative adjuvant treatment option for patients with stage III colorectal cancer. The study shows comparable disease-free survival rates between the 3-month and 6-month arms, while reducing the incidence of neurotoxicity.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong
Summary: The study evaluated the efficacy of bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer, finding that this combination showed significant disease control rates and survival outcomes in patients who had progressed with prior standard treatments.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Fernando Rivera, Marta Izquierdo-Manuel, Pilar Garcia-Alfonso, Eva Martinez de Castro, Javier Gallego, Maria Luisa Limon, Maria Alsina, Luis Lopez, Maica Galan, Esther Falco, Jose Luis Manzano, Encarna Gonzalez, Nerea Munoz-Unceta, Carlos Lopez, Enrique Aranda, Eva Fernandez, Monica Jorge, Paula Jimenez-Fonseca
Summary: The study suggests that perioperative XELOX-T is feasible and active in patients with HER2-positive GA and GEJA. Further investigation in randomized studies is warranted.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Guowei Kim, Hon Lyn Tan, Raghav Sundar, Bettina Lieske, Cheng Ean Chee, Jingshan Ho, Asim Shabbir, Maria Babak, Wee Han Ang, Boon Cher Goh, Wei Peng Yong, Lingzhi Wang, Jimmy B. Y. So
Summary: This study investigates the safety and tolerability of PIPAC oxaliplatin for peritoneal metastases from gastrointestinal tumors, concluding that the recommended phase II dose is 120 mg/m(2). Further studies are needed to clarify the efficacy and role of PIPAC oxaliplatin for peritoneal metastases.
CLINICAL CANCER RESEARCH
(2021)
Article
Surgery
Alexandra Nassar, Jean Marc Phelip, Diane Goere, Jerome Loriau, Claire Gallois, Pierre Michel, Christophe Penna, Julien Taieb, Antoine Brouquet, Stephane Benoist
Summary: This study reported the current clinical practice of French physicians for metachronous resectable liver metastasis occurring after a FOLFOX adjuvant chemotherapy for primary cancer. The results showed that preferred therapeutic approaches varied depending on different clinical situations, but there was consensus in the majority of cases.
WORLD JOURNAL OF SURGERY
(2021)
Article
Oncology
Manuela Robella, Michele De Simone, Paola Berchialla, Monica Argenziano, Alice Borsano, Shoeb Ansari, Ornella Abollino, Eleonora Ficiara, Armando Cinquegrana, Roberta Cavalli, Marco Vaira
Summary: This study investigates the maximum tolerable dose of cisplatin, doxorubicin, and oxaliplatin in PIPAC treatment, with the highest dosages achieved to date. Cohorts treated with higher doses tolerate PIPAC well, providing a basis for further clinical trials.
Article
Oncology
Thomas Ollila, James Butera, Pamela Egan, John Reagan, Anthony Thomas, Inna Yakirevich, Kelsey MacKinnon, Jeannine Margolis, Jessica McMahon, Valerie Rosati, Adam J. Olszewski
Summary: This study investigated the efficacy and safety of vincristine sulfate liposomal injection in combination with bendamustine and rituximab for indolent B-cell lymphoma. The results showed that the combination therapy was safe and effective, but due to observed toxicities and recurrences, the study did not proceed with an expanded cohort.
Article
Environmental Sciences
Manuela Robella, Paola Berchialla, Alice Borsano, Armando Cinquegrana, Alba Ilari Civit, Michele De Simone, Marco Vaira
Summary: PIPAC is a novel laparoscopic intraperitoneal chemotherapy approach for non-resectable peritoneal carcinomatosis. A model-based dose-escalation design is planned for oxaliplatin, cisplatin, and doxorubicin to optimize their doses applied in PIPAC. Safety is assessed according to CTCAE version 4.03 and secondary endpoints include radiological response and pharmacokinetic analyses.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2021)
Article
Oncology
Dong-Wook Kim, Won Jun Seo, Sang Il Youn, Ye Seob Jee, You-Jin Jang, Jong-Han Kim
Summary: This study determined the optimal dose of IP PTX combined with a systemic SOX regimen for treating peritoneal metastasis in advanced gastric cancer to be 80 mg/m(2). No dose-limiting toxicities were observed, and four patients showed a decrease in peritoneal cancer index score under this regimen.
JOURNAL OF GASTRIC CANCER
(2021)
